FDA's Coté, Director Of Orphan Products Development Office, Jumps To NORD
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will search for a new chief of its office just as interest in the rare disease space is increasing, particularly among large pharmaceutical companies.
You may also be interested in...
FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
FDA needs to formalize the flexibility it has employed in its rare disease program, according to Tim Coté, the National Organization for Rare Disorders’ new Chief Medical Officer and former head of the agency’s orphan products development program.
FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
FDA needs to formalize the flexibility it has employed in its rare disease program, according to Tim Coté, the National Organization for Rare Disorders’ new Chief Medical Officer and former head of the agency’s orphan products development program.
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.